



November 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-002664-10/ Novartis Protocol ID CNVA237B2301

A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma

Trial CNVA237B2301 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.